Personalised Medicine. research. Strategy 2025. University of Navarra
Among the priority objectives of the University of Navarra's Strategy 2025 is the promotion of impactful and focused research. In relation to this line of action, one of the lines of action seeks to promote innovation and translation in Personalised Medicine through the search for and implementation of new diagnostic and therapeutic solutions to address diseases for which there is still an unresolved clinical need. The aim is to improve the knowledge of diseases, whether of high or leave incidence, and above all to accompany patients and their families not only at the time of diagnosis and treatment, but also when the disease is in advanced stages.
This area of research is one of the University's greatest strengths, as it has researchers and research groups with a proven track record in this field. In this sense, the support of researchers and clinicians such as Dr Ignacio Gil-Bazo, Dr Gloria González-Aseguinolaza and Dr Carlos Centeno, who lead the work in Oncology, Rare Diseases and Palliative Medicine, respectively, should be highlighted. In a broader sense, there is also the strong support of a large number of researchers from different Schools of the University of Navarra, the University of Navarra, Tecnun - School of Engineering, the University of Navarra and the University of Navarra. Clínica Universidad de Navarra Tecnun - School of Engineering of the University of Navarra, and the Cima University of Navarra, who have been developing projects in this area for several years now.
The main motto of Strategy 2025 is "University and Sustainability". Therefore, research in Personalised Medicine is also aimed at contributing to the fulfilment of different Sustainable Goals of development (Health and Well-being, Quality Education, Industry, Innovation and Infrastructures, Establishment of Alliances to achieve Goals) and to the mission of the University. Finally, this Strategy is also a new opportunity to continue contributing to the strengthening of the health and biotechnology system, the establishment of public-private synergies in the field of health, and the promotion of the industrial fabric and the attraction of talent.
The objectives are:
Enable the use of state-of-the-art technologies to diagnose as early as possible and identify those groups of patients who share certain characteristics.
To develop new treatments, at the frontier of knowledge, that allow these pathologies to be tackled in a much more comprehensive and effective way.